

*Type of Review:* Extension of a currently approved collection.

*Respondents:* Not-for-profit institutions; State, local or Tribal governments.

*Number of Respondents and Responses:* 21,019 respondents with multiple responses; 27,737 responses.

*Estimated Time per Response:* .0025–12 hours.

*Frequency of Response:* Recordkeeping requirement; On occasion reporting requirement; Monthly reporting requirement; Third party disclosure requirement.

*Obligation To Respond:* Required to obtain or retain benefits. The statutory authority for this collection of information is contained in sections 154(i), 303, 308 and 325(a) of the Communications Act of 1934, as amended.

*Total Annual Burden:* 35,371 hours.  
*Total Annual Costs:* \$39,750.

*Privacy Act Impact Assessment:* This information collection does not affect individuals or households; thus, there are no impacts under the Privacy Act.

*Nature and Extent of Confidentiality:* There is no need for confidentiality with this information collection.

*Needs and Uses:* This submission is being made as an extension to an existing information collection pursuant to 44 U.S.C. 3507. This submission covers FCC Form 318 and its accompanying instructions and worksheets. FCC Form 318 is required: (1) To apply for a construction permit for a new Low Power FM (LPFM) station; (2) to make changes in the existing facilities of such a station; (3) to amend a pending FCC Form 318 application; or (4) to propose mandatory time-sharing.

Federal Communications Commission.

**Marlene Dortch,**

*Secretary, Office of the Secretary.*

[FR Doc. 2019-04567 Filed 3-12-19; 8:45 am]

**BILLING CODE 6712-01-P**

---

## FEDERAL ELECTION COMMISSION

### Sunshine Act Meeting

**TIME AND DATE:** Tuesday, March 19, 2019 at 10:00 a.m.

**PLACE:** 1050 First Street NE, Washington, DC.

**STATUS:** This meeting will be closed to the public.

**MATTERS TO BE CONSIDERED:** Compliance matters pursuant to 52 U.S.C. 30109.

Matters relating to internal personnel decisions, or internal rules and practices.

Investigatory records compiled for law enforcement purposes and

production would disclose investigative techniques.

Information the premature disclosure of which would be likely to have a considerable adverse effect on the implementation of a proposed Commission action.

Matters concerning participation in civil actions or proceedings or arbitration.

\* \* \* \* \*

**CONTACT PERSON FOR MORE INFORMATION:** Judith Ingram, Press Officer, Telephone: (202) 694-1220.

**Laura E. Sinram,**

*Deputy Secretary of the Commission.*

[FR Doc. 2019-04666 Filed 3-11-19; 11:15 am]

**BILLING CODE 6715-01-P**

---

## FEDERAL MARITIME COMMISSION

### Notice of Agreements Filed

The Commission hereby gives notice of the filing of the following agreements under the Shipping Act of 1984. Interested parties may submit comments on the agreements to the Secretary by email at [Secretary@fmc.gov](mailto:Secretary@fmc.gov), or by mail, Federal Maritime Commission, Washington, DC 20573, within twelve days of the date this notice appears in the **Federal Register**. Copies of agreements are available through the Commission's website ([www.fmc.gov](http://www.fmc.gov)) or by contacting the Office of Agreements at (202)-523-5793 or [tradeanalysis@fmc.gov](mailto:tradeanalysis@fmc.gov).

*Agreement No.:* 201229-002.

*Agreement Name:* Marine Terminal Services Agreement Port of Houston Authority and Maersk Line A/S.

*Parties:* Port of Houston Authority and Maersk Line A/S.

*Filing Party:* Chasless Yancy; Port of Houston Authority.

*Synopsis:* The amendment revises the Consumer Price Index adjustment month for the MTSA from October to July.

*Proposed Effective Date:* 3/6/2019.

*Location:* <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/2076>.

*Agreement No.:* 012212-004.

*Agreement Name:* NYK/Grimaldi Cooperative Working Agreement.

*Parties:* Nippon Yusen Kaisha; and Grimaldi Deep Sea S.P.A. and Grimaldi Euromed S.P.A. (acting as a single party).

*Filing Party:* Wayne Rohde; Cozen O'Connor.

*Synopsis:* The amendment converts the Agreement from a one-way space charter to a reciprocal space charter arrangement.

*Proposed Effective Date:* 3/6/2019.

*Location:* <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/262>.

*Agreement No.:* 201291.

*Agreement Name:* Turkon/Hapag-Lloyd Space Charter and Sailing Agreement.

*Parties:* Hapag-Lloyd AG and Turkon Konteyner Tasimacilik ve Denizcilik A.S.

*Filing Party:* Wayne Rohde; Cozen O'Connor.

*Synopsis:* The Agreement authorizes the parties to operate a service between the U.S. Atlantic Coast and ports in Spain, Turkey, and Egypt. The parties request expedited review.

*Proposed Effective Date:* 4/21/2019.

*Location:* <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/21339>.

Dated: March 8, 2019,

**Rachel Dickon,**

*Secretary.*

[FR Doc. 2019-04637 Filed 3-12-19; 8:45 am]

**BILLING CODE 6731-AA-P**

---

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2019-D-0358]

#### Cancer Clinical Trial Eligibility Criteria: Minimum Age for Pediatric Patients; Draft Guidance for Industry; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Cancer Clinical Trial Eligibility Criteria: Minimum Age for Pediatric Patients." This draft guidance is one in a series of guidances that provide recommendations regarding eligibility criteria for clinical trials of drugs or biological products regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) for the treatment of cancer. Specifically, this guidance includes recommendations on the inclusion of pediatric patients (*i.e.*, children and adolescents) in clinical trials for cancer treatments. Broadening cancer trial eligibility criteria can maximize the generalizability of trial results and the ability to understand the therapy's benefit-risk profile across the patient population likely to use the